Carisma Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Carisma Therapeutics
CARM Stock   0.05  0.01  14.29%   
Carisma Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Carisma Therapeutics' valuation are provided below:
Gross Profit
25.3 M
Profit Margin
0.1528
Market Capitalization
2 M
Enterprise Value Revenue
1.0201
Revenue
52.6 M
There are over one hundred nineteen available fundamental signals for Carisma Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Carisma Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

Carisma Therapeutics Total Revenue

12.89 Million

Check Carisma Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carisma Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 2 M or Selling General Administrative of 24.3 M, as well as many indicators such as Price To Sales Ratio of 0.97, Dividend Yield of 0.096 or Days Sales Outstanding of 58.17. Carisma financial statements analysis is a perfect complement when working with Carisma Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Carisma Stock
Check out the analysis of Carisma Therapeutics Correlation against competitors.
To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.

Carisma Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.3 M35 M75.6 M
Slightly volatile
Short and Long Term Debt Total2.7 M2.9 M6.1 M
Pretty Stable
Other Current Liabilities14.8 M14.1 M6.4 M
Slightly volatile
Total Current Liabilities10 M18.5 M9.3 M
Slightly volatile
Property Plant And Equipment Net7.8 M7.4 M3.1 M
Slightly volatile
Accounts Payable2.1 M2.4 M1.9 M
Slightly volatile
Cash19.6 M20.6 M36.7 M
Slightly volatile
Non Current Assets Total7.2 M7.6 M32.2 M
Pretty Stable
Non Currrent Assets Other227.2 K239.2 K931.3 K
Pretty Stable
Cash And Short Term Investments20.6 M21.7 M38.5 M
Slightly volatile
Common Stock Shares Outstanding50.1 M47.7 M14.2 M
Slightly volatile
Liabilities And Stockholders Equity33.3 M35 M75.6 M
Slightly volatile
Non Current Liabilities Total73.1 M48.7 M61.9 M
Slightly volatile
Other Current Assets3.4 M2.4 M2.9 M
Slightly volatile
Other Stockholder Equity192.9 M319.3 M174.6 M
Slightly volatile
Total Liabilities83.1 M67.1 M71.2 M
Slightly volatile
Total Current Assets53.6 M27.4 M45 M
Slightly volatile
Short Term Debt2 M2 M1.5 M
Slightly volatile
Common Stock55.6 K47.1 K47.8 K
Slightly volatile
Current Deferred Revenue4.5 M4.3 M1.8 M
Slightly volatile
Other Assets1.091.1512.4 K
Pretty Stable
Good Will11 M11.8 M14.4 M
Slightly volatile
Intangible Assets12.6 M13.2 M40.8 M
Slightly volatile
Capital Lease Obligations2.9 M2.2 M3.4 M
Pretty Stable
Property Plant And Equipment Gross13 M16.5 M8.7 M
Slightly volatile
Capital Stock35.1 K36.9 K65.6 M
Slightly volatile
Net Working Capital6.6 M7 M39.1 M
Slightly volatile
Property Plant Equipment8.9 M15.5 M7.5 M
Slightly volatile
Net Receivables2.4 M2.6 M18 M
Slightly volatile
Long Term Debt27 M30.3 M33.1 M
Slightly volatile
Deferred Long Term Liabilities3.3 M3.7 M4 M
Slightly volatile
Non Current Liabilities Other271.9 K286.2 K902.1 K
Slightly volatile

Carisma Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4 M3.9 M1.1 M
Slightly volatile
Interest Expense2 M2.2 M1.7 M
Slightly volatile
Selling General Administrative24.3 M23.2 M11.6 M
Slightly volatile
Other Operating Expenses98.8 M94.1 M45.2 M
Slightly volatile
Research Development72.1 M68.6 M31.9 M
Slightly volatile
Total Operating Expenses33.6 M25.5 M29.4 M
Slightly volatile
Total Revenue12.9 M22.6 M10.5 M
Slightly volatile
Cost Of Revenue72.1 M68.6 M16.7 M
Slightly volatile
Selling And Marketing Expenses11.6 M9.5 M12.5 M
Slightly volatile
Interest Income1 M2 M521.9 K
Slightly volatile
Reconciled Depreciation2 M3.9 M1.2 M
Slightly volatile

Carisma Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.4 M4.2 M1.8 M
Slightly volatile
Begin Period Cash Flow93.7 M89.2 M41.6 M
Slightly volatile
Depreciation4 M3.9 M1.4 M
Slightly volatile
Other Non Cash Items9.3 M6.3 M7.9 M
Pretty Stable
End Period Cash Flow35 M20.6 M29.5 M
Slightly volatile
Dividends Paid117.6 K132.3 K144.4 K
Slightly volatile
Change To Netincome1.1 M1.2 M1.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.971.0233.6371
Slightly volatile
Dividend Yield0.0960.110.1208
Slightly volatile
Days Sales Outstanding58.1761.23254
Slightly volatile
Stock Based Compensation To Revenue0.20.210.6922
Slightly volatile
Capex To Depreciation0.04010.04220.6929
Slightly volatile
Payables Turnover27.125.817.1305
Slightly volatile
Sales General And Administrative To Revenue1.121.183.1672
Slightly volatile
Research And Ddevelopement To Revenue3.323.58.0239
Slightly volatile
Capex To Revenue0.00680.00720.0842
Very volatile
Cash Per Share0.50.5214.7261
Slightly volatile
Days Payables Outstanding13.9114.643.4 K
Very volatile
Income Quality0.891.140.8398
Very volatile
Intangibles To Total Assets0.0970.10.4656
Slightly volatile
Current Ratio1.271.344.7002
Very volatile
Receivables Turnover3.186.172.5247
Slightly volatile
Capex Per Share0.00320.00340.3075
Slightly volatile
Revenue Per Share0.520.543.3066
Pretty Stable
Interest Debt Per Share0.06540.06883.6909
Slightly volatile
Debt To Assets0.0890.09370.3612
Slightly volatile
Graham Number30.7934.6437.8086
Slightly volatile
Operating Cycle58.1761.23254
Slightly volatile
Days Of Payables Outstanding13.9114.643.4 K
Very volatile
Ebt Per Ebit0.880.97261.0704
Very volatile
Quick Ratio1.271.344.7002
Very volatile
Net Income Per E B T0.04260.04490.4421
Slightly volatile
Cash Ratio0.951.04.1919
Very volatile
Days Of Sales Outstanding58.1761.23254
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.860.91.0373
Very volatile
Fixed Asset Turnover2.612.7556.1602
Pretty Stable
Debt Ratio0.0890.09370.3612
Slightly volatile
Price Sales Ratio0.971.0233.6371
Slightly volatile
Asset Turnover0.610.580.1904
Slightly volatile

Carisma Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.9 M15.6 M17.1 M
Slightly volatile
Enterprise Value1.5 M1.7 M1.9 M
Slightly volatile

Carisma Fundamental Market Drivers

Carisma Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Carisma Therapeutics Financial Statements

Carisma Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Carisma Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.3 M4.5 M
Total Revenue22.6 M12.9 M
Cost Of Revenue68.6 M72.1 M
Stock Based Compensation To Revenue 0.21  0.20 
Sales General And Administrative To Revenue 1.18  1.12 
Research And Ddevelopement To Revenue 3.50  3.32 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.54  0.52 
Ebit Per Revenue(2.85)(2.99)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Carisma Therapeutics is a strong investment it is important to analyze Carisma Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Carisma Therapeutics' future performance. For an informed investment choice regarding Carisma Stock, refer to the following important reports:
How To Invest In Carisma
Details
Is Carisma Stock a good investment?
Details
What is Carisma Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Carisma Therapeutics Correlation against competitors.
To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.19
Revenue Per Share
1.26
Quarterly Revenue Growth
12.368
Return On Assets
0.3304
Return On Equity
(3.63)
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY